Latest 10-K annual reports

Delcath Systems, Inc. reported a significant increase in revenue for 2025, driven by the commercial expansion of HEPZATO KIT in the US and CHEMOSAT in Europe, alongside positive clinical trial results for combination therapies.

Sterling Infrastructure, Inc. announced robust financial results for fiscal year 2025, driven by significant E-Infrastructure growth and strategic acquisitions, alongside a record-high backlog.

Fate Therapeutics, a clinical-stage biopharmaceutical company, reported reduced net losses in 2025 while advancing its iPSC-derived cellular immunotherapy pipeline for autoimmune diseases and cancer.

Centuri Holdings, Inc. announced a seventh amendment to its credit agreement, repricing its term loan with lower interest margins, and reported a 13.1% increase in revenue for fiscal year 2025.

CBIZ, Inc. announced a significant revenue and net income increase in 2025, primarily fueled by the successful integration of the Marcum LLP acquisition.

Vericel Corporation achieved significant revenue and net income growth in 2025, fueled by strong MACI sales and NexoBrid expansion, while advancing its product pipeline.

Gibraltar Industries reported a net loss of $44.4 million in 2025, primarily due to a significant impairment charge from discontinued operations, while strategically acquiring OmniMax for $1.335 billion in early 2026.

SM Energy finalized its Civitas merger, expanded its asset portfolio, announced a significant South Texas asset divestiture, and increased its annual dividend.

Archrock, Inc. delivered significant revenue and net income growth in 2025, fueled by strategic acquisitions and robust demand for natural gas compression services.

Standard Motor Products achieved significant revenue and profit growth in 2025, largely fueled by the full-year inclusion of Nissens Automotive, despite an identified material weakness in internal controls.

Playtika Holding Corp. reported a significant net loss of $206.4 million in 2025, driven by increased operating expenses and contingent consideration adjustments, despite revenue growth from recent acquisitions.

Disc Medicine received a Complete Response Letter from the FDA for bitopertin's accelerated approval in EPP and XLP, while reporting increased net losses and a strong cash position.

Alkami Technology, Inc. announced robust 2025 financial results, driven by significant revenue and user growth, alongside the strategic acquisition of MANTL to expand its digital banking platform.

Medical Properties Trust reports a significantly reduced net loss in 2025, driven by debt refinancing and strategic re-tenanting efforts, despite ongoing tenant bankruptcies.

Arch Capital Group Ltd. reported robust financial performance for 2025, driven by strong underwriting and investment returns across its diversified insurance, reinsurance, and mortgage segments.

Pulmatrix is shifting its strategic focus to a merger with Cullgen Inc., pausing all internal drug development while seeking to monetize its existing iSPERSE-based assets.

Hertz Global Holdings, Inc. reported a significantly reduced net loss and improved Adjusted Corporate EBITDA in 2025, driven by fleet management and revenue optimization efforts, despite a decline in overall revenues.

CRA International, a global consulting firm, announced a 9.3% revenue increase to $751.6 million and a 17.3% rise in net income to $54.8 million for fiscal year 2025, alongside an expanded share repurchase program and increased dividends.

MannKind Corporation reported a 22% increase in total revenue for 2025, driven by product sales and collaborations, alongside strategic acquisitions and pipeline advancements.

International Seaways, Inc. reported strong financial results for 2025, marked by strategic fleet optimization, significant debt reduction, and increased liquidity, despite a decrease in overall revenues.

Heron Therapeutics reports increased net product sales driven by strong acute care performance, despite a net loss and ongoing patent litigation for its oncology products.

Edgewise Therapeutics, Inc. filed its annual 10-K report for the fiscal year ended December 31, 2025, detailing significant progress in its muscular dystrophy and cardiac disease clinical programs, alongside increased net losses and ongoing capital requirements.

The Pennant Group, Inc. announced significant revenue and net income growth in 2025, driven by robust organic expansion and strategic acquisitions across its home health, hospice, and senior living segments.

Burford Capital Limited reported a significant decrease in total revenues and net income for the fiscal year ended December 31, 2025, primarily driven by lower net realized gains from capital provision assets.

Lantheus Holdings, Inc. reports strategic divestitures, key acquisitions, and pipeline advancements in 2025, alongside leadership changes and PYLARIFY revenue adjustments.

Wave Life Sciences reported increased net losses in 2025 despite positive clinical trial data for its lead RNA medicine programs and a significant capital raise.

C4 Therapeutics reports 2025 financial results, pipeline progress, and a significant capital raise, extending its operational runway through 2028.

Cronos Group Inc. reported a significant increase in net revenue and improved Adjusted EBITDA for 2025, driven by international expansion and operational efficiencies, despite a net loss.

Akebia Therapeutics saw significant revenue growth in 2025, primarily from the U.S. launch of Vafseo, while navigating generic competition for Auryxia and advancing its rare kidney disease pipeline.

Collegium Pharmaceutical, Inc. announced a significant increase in net product revenues for 2025, primarily fueled by the full-year contribution of Jornay PM and strategic acquisitions.